Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6965230rdf:typepubmed:Citationlld:pubmed
pubmed-article:6965230lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6965230lifeskim:mentionsumls-concept:C0005682lld:lifeskim
pubmed-article:6965230lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:6965230lifeskim:mentionsumls-concept:C0039593lld:lifeskim
pubmed-article:6965230lifeskim:mentionsumls-concept:C0016441lld:lifeskim
pubmed-article:6965230pubmed:issue2lld:pubmed
pubmed-article:6965230pubmed:dateCreated1988-6-20lld:pubmed
pubmed-article:6965230pubmed:abstractTextA total of 143 patients with transitional cell carcinoma of the urinary bladder were tested for lymphocyte-mediated cytotoxicity against the bladder carcinoma cell line T24. Some of the patients were also tested against MANO (another cell line of transitional cell bladder carcinoma origin), HCV29 (from bladder epithelium, probably transformed in vitro) and/or HT29 (from a colon adenocarcinoma). The patients were divided into a high- or a low-responder group for each cell line. The patients were followed up and the correlation between a high response in the cytotoxicity tests and survival was evaluated using an adaptation of the Mantel-Haenszel statistics. No significant correlation could be demonstrated.lld:pubmed
pubmed-article:6965230pubmed:languageenglld:pubmed
pubmed-article:6965230pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6965230pubmed:citationSubsetIMlld:pubmed
pubmed-article:6965230pubmed:statusMEDLINElld:pubmed
pubmed-article:6965230pubmed:issn0340-7004lld:pubmed
pubmed-article:6965230pubmed:authorpubmed-author:LarssonAAlld:pubmed
pubmed-article:6965230pubmed:authorpubmed-author:TroyeMMlld:pubmed
pubmed-article:6965230pubmed:authorpubmed-author:NäslundIIlld:pubmed
pubmed-article:6965230pubmed:issnTypePrintlld:pubmed
pubmed-article:6965230pubmed:volume14lld:pubmed
pubmed-article:6965230pubmed:ownerNLMlld:pubmed
pubmed-article:6965230pubmed:authorsCompleteYlld:pubmed
pubmed-article:6965230pubmed:pagination82-5lld:pubmed
pubmed-article:6965230pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:meshHeadingpubmed-meshheading:6965230-...lld:pubmed
pubmed-article:6965230pubmed:year1982lld:pubmed
pubmed-article:6965230pubmed:articleTitleA follow-up study of urinary bladder patients tested for tumour-related lymphocyte-mediated cytotoxicity.lld:pubmed
pubmed-article:6965230pubmed:affiliationDepartment of Immunology, University of Stockholm, Sweden.lld:pubmed
pubmed-article:6965230pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6965230pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed